<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00496106</url>
  </required_header>
  <id_info>
    <org_study_id>2005-4526</org_study_id>
    <secondary_id>R01CA118136-01A1</secondary_id>
    <nct_id>NCT00496106</nct_id>
  </id_info>
  <brief_title>Stress, Immunity and Cervical Cancer: Biobehavioral Outcomes</brief_title>
  <acronym>CXR01</acronym>
  <official_title>Stress, Immunity &amp; Cervical Cancer: Biobehavioral Outcomes of a Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Irvine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to:&#xD;
&#xD;
        1. Test the efficacy of psychosocial telephone counseling (PTC) for cervical cancer&#xD;
           survivors, compared to usual care.&#xD;
&#xD;
        2. Evaluate the longitudinal immune and neuroendocrine parameters in cervical cancer&#xD;
           patients who have received PTC, compared to usual care.&#xD;
&#xD;
        3. Examine the longitudinal relationship between PTC associated modulations of quality of&#xD;
           life (QOL) measures and biologic parameters (immune and neuroendocrine).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The incidence and mortality rates for invasive cervical cancer in minority, low-income, and&#xD;
      less educated women exceeds that for white, higher income, and better educated women. In&#xD;
      southern California the incidence and mortality rates for cervical cancer are nearly twice&#xD;
      that of non-Latina white women. Our preliminary work supports and extends the extant&#xD;
      literature, noting that quality of life can be significantly disrupted among cervical cancer&#xD;
      survivors, with qualitative differences in how Latina women experience cancer survivorship.&#xD;
      However, there is a paucity of literature on interventions designed to assist cervical cancer&#xD;
      survivors manage illness-specific stress and improve health behaviors. Our current NIH-funded&#xD;
      work suggests that a six session psychosocial telephone counseling (PTC) intervention can&#xD;
      improve QOL and decrease psychological distress, with accompanying intervention-induced&#xD;
      neuroendocrine and immune parameter modulations which may be related to disease endpoints. In&#xD;
      primary support of these significant biobehavioral findings, the project herein proposes to&#xD;
      accomplish the following Specific Aims:&#xD;
&#xD;
        1. Test the efficacy of PTC for cervical cancer survivors, compared to usual care.&#xD;
&#xD;
        2. Evaluate the longitudinal immune and neuroendocrine parameters in cervical cancer&#xD;
           patients who have received PTC, compared to usual care.&#xD;
&#xD;
        3. Examine the longitudinal relationship between PTC associated modulations of QOL measures&#xD;
           and biologic parameters (immune and neuroendocrine).&#xD;
&#xD;
      To achieve these aims the investigators will randomize patients ascertained through the two&#xD;
      SEER cancer registries to PTC (N=125) or usual care (N=125), stratifying on English or&#xD;
      Spanish language preference. Assessments will occur at baseline (9-20 months post diagnosis),&#xD;
      and three and nine months post enrollment/baseline. Assessments will include evaluation of&#xD;
      QOL (overall QOL, psychological distress, coping, social support, sexual functioning), health&#xD;
      behaviors, neuroendocrine parameters dehydroepiandrosterone sulfate, growth hormone [DHEA-S,&#xD;
      cortisol, GH] and immunologic parameters (natural killers [NK] cell activity, IL-5,&#xD;
      interferon, human papillomavirus (HPV) E6/E7 peptides, IL-15, IL 10). This project has&#xD;
      significant public health relevance for an important unstudied cancer survivor population,&#xD;
      many of whom are poor and underserved. If effective, an intervention which could improve&#xD;
      quality of life (QOL) and health behaviors, and enhance neuroendocrine and immune responses&#xD;
      for women with cervical cancer could have significant implications toward disease recurrence&#xD;
      or survival.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the efficacy of a multicomponent biobehavioral psychosocial telephone counseling (PTC) intervention for cervical cancer survivors, compared to usual care</measure>
    <time_frame>10 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the longitudinal immune and neuroendocrine parameters in cervical cancer patients who have received the PTC intervention, compared to usual care</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">204</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 telephone counseling sessions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6 telephone counseling sessions</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Telephone counseling</intervention_name>
    <description>6 telephone counseling sessions</description>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_label>Usual Care Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Telephone interview</intervention_name>
    <description>telephone interview</description>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_label>Usual Care Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Cervical cancer (stage I, II, or III) patients who have completed definitive treatment&#xD;
             at least 2 months earlier and who were diagnosed between 9 and 20 months prior to&#xD;
             enrollment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Stage IV cervical cancer.&#xD;
&#xD;
          -  Have undergone previous treatment with biological response modifier or prior&#xD;
             immunotherapy within 4 weeks of study enrollment.&#xD;
&#xD;
          -  Used investigational drugs within 30 days.&#xD;
&#xD;
          -  Were under immune suppression for any reason.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lari B Wenzel, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Irvine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Irvine Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>July 2, 2007</study_first_submitted>
  <study_first_submitted_qc>July 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2007</study_first_posted>
  <last_update_submitted>March 5, 2019</last_update_submitted>
  <last_update_submitted_qc>March 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Irvine</investigator_affiliation>
    <investigator_full_name>Lari Wenzel</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

